All Stories

  1. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review

    Article • Journal of Neurosurgery, September 2017, Journal of Neurosurgery Publishing Group (JNSPG)

    Dr Alexandru SAVEANU

  2. LHX4 et déficit hypophysaire congénital : nouveaux variants, nouveau phénotype, nouvelle surveillance

    Article • Annales d Endocrinologie, October 2014, Elsevier

    Dr Alexandru SAVEANU

  3. Hypopituitarisme congénital : description phénotypique et analyse génétique de 990 patients. Expérience du réseau Genhypopit

    Article • Annales d Endocrinologie, October 2014, Elsevier

    Dr Alexandru SAVEANU

  4. Combined pituitary hormone deficiency: current and future status

    Article • Journal of Endocrinological Investigation, September 2014, Springer Science + Business Media

    Dr Alexandru SAVEANU

  5. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures

    Article • July 2014, Bioscientifica

    Dr Alexandru SAVEANU, Professor Tullio Florio

  6. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies

    Article • Drug Discovery Today, April 2014, Elsevier

    Dr Alexandru SAVEANU, Professor Tullio Florio

  7. Targeting Dopamine Receptors Subtype 2 (D2DR) in Pheochromocytomas: Head-to-Head Comparison Between In Vitro and In Vivo Findings

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2013, Endocrine Society

    Dr Alexandru SAVEANU

  8. Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report

    Article • Pituitary, July 2012, Springer Science + Business Media

    Dr Alexandru SAVEANU

  9. PROKR2 Variants in Multiple Hypopituitarism with Pituitary Stalk Interruption

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2012, Endocrine Society

    Dr Alexandru SAVEANU

  10. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: Impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion

    Article • Molecular and Cellular Endocrinology, May 2012, Elsevier

    Dr Alexandru SAVEANU

  11. Genetic causes of combined pituitary hormone deficiencies in humans

    Article • Annales d Endocrinologie, April 2012, Elsevier

    Dr Alexandru SAVEANU

  12. Phenotypic Homogeneity and Genotypic Variability in a Large Series of Congenital Isolated ACTH-Deficiency Patients withTPITGene Mutations

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2012, Endocrine Society

    Dr Alexandru SAVEANU

  13. Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins

    Article • Clinical Endocrinology, February 2012, Wiley

    Dr Alexandru SAVEANU, Professor Tullio Florio

  14. Case seminar: a young female with acute hyponatremia and a sellar mass

    Article • Endocrine, August 2011, Springer Science + Business Media

    Dr Alexandru SAVEANU

  15. Quelles causes génétiques rechercher en présence d’un déficit en hormone de croissance ?

    Article • Archives de Pédiatrie, June 2011, Elsevier

    Dr Alexandru SAVEANU

  16. Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy

    Article • Annals of the New York Academy of Sciences, March 2011, Wiley

    Dr Alexandru SAVEANU

  17. Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas

    Article • February 2011

    Dr Alexandru SAVEANU

  18. Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms

    Article • January 2011

    Dr Alexandru SAVEANU

  19. Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency

    Article • Pituitary, December 2010, Springer Science + Business Media

    Dr Alexandru SAVEANU, Professor Gudmundur Johannsson

  20. Effet de l’octréotide et du SOM 230 sur la viabilité cellulaire de méningiomes in vitro

    Article • Neurochirurgie, December 2010, Elsevier

    Dr Alexandru SAVEANU

  21. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5

    Article • Pituitary, November 2010, Springer Science + Business Media

    Dr Alexandru SAVEANU, Professor Tullio Florio

  22. A Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2010, Endocrine Society

    Dr Alexandru SAVEANU

  23. Ciblage des récepteurs de la somatostatine dans les tumeurs neuroendocrines gastroentéropancréatiques (TNE-GEP) : quels radiotraceurs pour quelles tumeurs ?

    Article • Médecine Nucléaire, May 2010, Elsevier

    Dr Alexandru SAVEANU

  24. Donnees genetiques actuelles

    Article • Journal de Radiologie, October 2009, Elsevier

    Dr Alexandru SAVEANU

  25. Lanreotide for the treatment of acromegaly

    Article • Advances in Therapy, June 2009, Springer Science + Business Media

    Dr Alexandru SAVEANU

  26. Mécanismes de tumorigenèse hypophysaire

    Article • La Presse Médicale, January 2009, Elsevier

    Dr Alexandru SAVEANU

  27. Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas

    Article • Cancer Research, December 2008, American Association for Cancer Research (AACR)

    Dr Alexandru SAVEANU

  28. Congenital pituitary hormone deficiencies: role ofLHX3/LHX4genes

    Article • Expert Review of Endocrinology & Metabolism, November 2008, Taylor & Francis

    Dr Alexandru SAVEANU

  29. OR2,6 Interrelationship between somatostatin/dopamine pathways and growth factors in non-small lung cancer cells

    Article • Growth Hormone & IGF Research, September 2008, Elsevier

    Dr Alexandru SAVEANU

  30. Somatostatin–dopamine ligands in the treatment of pituitary adenomas

    Article • Reviews in Endocrine and Metabolic Disorders, July 2008, Springer Science + Business Media

    Dr Alexandru SAVEANU

  31. A Novel Dysfunctional LHX4 Mutation with High Phenotypical Variability in Patients with Hypopituitarism

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2008, Endocrine Society

    Dr Alexandru SAVEANU

  32. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study

    Article • June 2008

    Dr Alexandru SAVEANU, Professor Tullio Florio

  33. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas

    Article • Molecular and Cellular Endocrinology, May 2008, Elsevier

    Dr Alexandru SAVEANU

  34. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

    Article • May 2008

    Dr Alexandru SAVEANU

  35. Déficit hypophysaire combiné multiple : aspects cliniques et génétiques

    Article • Annales d Endocrinologie, February 2008, Elsevier

    Dr Alexandru SAVEANU

  36. Rapid Pituitary Tumor Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient

    Article • The Journal of Clinical Endocrinology & Metabolism, May 2007, Endocrine Society

    Dr Alexandru SAVEANU

  37. Novel chimeric somatostatin analogs: facts and perspectives

    Article • April 2007

    Dr Alexandru SAVEANU

  38. saveanu

    Article • Acta Endocrinologica (Bucharest), January 2007, ACTA Endocrinologica Foundation

    Dr Alexandru SAVEANU

  39. Identification and Functional Analysis of the Novel S179RPOU1F1Mutation Associated with Combined Pituitary Hormone Deficiency

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2006, Endocrine Society

    Dr Alexandru SAVEANU

  40. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies

    Article • November 2006

    Dr Alexandru SAVEANU

  41. Genetic Screening of Combined Pituitary Hormone Deficiency: Experience in 195 Patients

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2006, Endocrine Society

    Dr Alexandru SAVEANU

  42. Somatostatin and Dopamine-Somatostatin Multiple Ligands Directed towards Somatostatin and Dopamine Receptors in Pituitary Adenomas

    Article • Neuroendocrinology, January 2006, Karger Publishers

    Dr Alexandru SAVEANU

  43. An Uncommon Phenotype with Familial Central Hypogonadism Caused by a NovelPROP1Gene Mutant Truncated in the Transactivation Domain

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2005, Endocrine Society

    Dr Alexandru SAVEANU

  44. Novel Mutations within thePOU1F1Gene Associated with Variable Combined Pituitary Hormone Deficiency

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2005, Endocrine Society

    Dr Alexandru SAVEANU, Dr Anatoly Tiulpakov

  45. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy

    Article • June 2005

    Dr Alexandru SAVEANU

  46. Génétique des hypopituitarismes antérieurs

    Article • Annales d Endocrinologie, June 2005, Elsevier

    Dr Alexandru SAVEANU

  47. Novel modalities of somatostatin actions

    Article • December 2004

    Dr Alexandru SAVEANU

  48. Pituitary hormone deficiencies due to transcription factor gene alterations

    Article • Growth Hormone & IGF Research, December 2004, Elsevier

    Dr Alexandru SAVEANU

  49. P222 - Expression quantitative des arnm de récepteurs de la somatostatine (sst2 et sst5) et dopamine d2 (d2dr) dans les tumeurs endocrines digestives

    Article • Annales d Endocrinologie, September 2004, Elsevier

    Dr Alexandru SAVEANU

  50. Hypopituitarisme congénital

    Article • La Presse Médicale, March 2004, Elsevier

    Dr Alexandru SAVEANU

  51. Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2002, Endocrine Society

    Dr Alexandru SAVEANU

  52. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies

    Article • July 2001

    Dr Alexandru SAVEANU

  53. BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2001, Endocrine Society

    Dr Alexandru SAVEANU

  54. BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas1

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2001, Endocrine Society

    Dr Alexandru SAVEANU

  55. Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral Phenotypes1

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2000, Endocrine Society

    Dr Alexandru SAVEANU

  56. Quantitative and Functional Expression of Somatostatin Receptor Subtypes in Human Prolactinomas1

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1999, Endocrine Society

    Dr Alexandru SAVEANU